Cynomolgus LILRB2/CD85d/ILT4 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Cynomolgus LILRB2/CD85d/ILT4 Protein is expressed from HEK293 with hFc tag at the C-Terminus.
It contains Gly24-Arg457 [Accession | XP_015297203.1].

分子量大小(Molecular Weight)

The protein has a predicted MW of 71.68 kDa. Due to glycosylation, the protein migrates to 80-90 kDa based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Cynomolgus LILRB2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SPR Data

Cynomolgus LILRB2, hFc Tag captured on CM5 Chip via Protein A can bind Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His Tag with an affinity constant of 42.50 nM as determined in SPR assay (Biacore T200).

背景(Background)

The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC). LILRB2 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles.

分子别名(Synonyms)

CD85d; ILT4; ILT-4; ILT4CD85d; LILRB2; LIR2; MIR10

文献(References)

(1)Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.J Clin Invest. 2018;128(12):5647-5662.